Last $60.35 USD
Change Today -2.77 / -4.39%
Volume 17.6M
ABBV On Other Exchanges
Symbol
Exchange
New York
EN Paris
Mexico
Frankfurt
As of 8:04 PM 01/30/15 All times are local (Market data is delayed by at least 15 minutes).

abbvie inc (ABBV) Snapshot

Open
$62.09
Previous Close
$63.12
Day High
$62.68
Day Low
$60.12
52 Week High
12/8/14 - $70.76
52 Week Low
04/11/14 - $45.50
Market Cap
96.2B
Average Volume 10 Days
8.9M
EPS TTM
$2.88
Shares Outstanding
1.6B
EX-Date
01/13/15
P/E TM
21.0x
Dividend
$1.96
Dividend Yield
2.90%
Current Stock Chart for ABBVIE INC (ABBV)

abbvie inc (ABBV) Details

AbbVie Inc. discovers, develops, manufactures, and sells pharmaceutical products worldwide. Its products include adult and pediatric pharmaceuticals, such as HUMIRA, a biologic therapy administered as a subcutaneous injection to treat autoimmune diseases; Synthroid to treat hypothyroidism; AndroGel, a daily testosterone replacement therapy; Creon, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Kaletra, a prescription anti-HIV-1 medicine used with other anti-HIV-1 medications to increase the chance of treatment response in people with HIV-1; Norvir , a protease inhibitor indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection; and Lupron, a product for the palliative treatment of advanced prostate cancer. The company also offers TriCor and TRILIPIX, which are fibric acid derivatives that are indicated as adjuncts to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels; Niaspan, an extended release form of niacin that is indicated as an adjunct to diet to reduce total cholesterol, LDL cholesterol, and triglyceride levels, as well as to increase HDL cholesterol levels; Synagis, which protects at-risk infants from severe respiratory disease or respiratory syncytial virus; Sevoflurane, an anesthesia product for human use; Duodopa, a levodopa-carbidopa intestinal gel used to treat advanced Parkinson's disease; and Zemplar used for the prevention and treatment of secondary hyperparathyroidism. It sells its products to wholesalers, distributors, government agencies, health care facilities, specialty pharmacies, and independent retailers from its distribution centers and public warehouses. It has a strategic collaboration with Infinity Pharmaceuticals, Inc.; and a research and development collaboration with California Life Sciences LLC. AbbVie Inc. was incorporated in 2012 and is based in North Chicago, Illinois. As of January 01, 2013, AbbVie Inc. operates independently of Abbott Laboratories.

abbvie inc (ABBV) Top Compensated Officers

Chairman, Chief Executive Officer and Chairma...
Total Annual Compensation: $1.5M
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $790.0K
Executive Vice President of Commercial Operat...
Total Annual Compensation: $710.0K
Executive Vice President of Business Developm...
Total Annual Compensation: $900.0K
Senior Vice President of Human Resources
Total Annual Compensation: $545.0K
Compensation as of Fiscal Year 2013.

abbvie inc (ABBV) Key Developments

AbbVie Announces Top-line Results from Phase 3 Study of All-Oral Treatment for Hepatitis C in Japan

AbbVie released top-line Phase 3 results for its investigational, all-oral, ribavirin (RBV)-free, two direct-acting antiviral treatment with ombitasvir/paritaprevir/ritonavir (OBV/PTV/r) in patients with genotype 1b (GT1b) chronic hepatitis C virus (HCV) infection in Japan. The primary endpoint of the GIFT-I study was achieved, demonstrating a 95% (n=106/112) sustained virologic response rate at 12 weeks post treatment (SVR12) in the sub-group of previously untreated, non-cirrhotic adult GT1b Japanese patients who were eligible for therapy with interferon (IFN) and had a high viral load. In the GIFT-I study, the primary efficacy population comprised a sub-group of treatment-naive GT1b chronic HCV infected patient population. This sub-group consisted of treatment-naive patients without cirrhosis who were eligible for therapy with IFN with or without RBV, had a high viral load (> 100,000 IU/mL) and received at least one dose of the double-blind active study drug. The primary endpoint was assessed at 12 weeks post treatment (SVR12).

Missouri's Medicaid selects AbbVie's Viekira Pak as preferred HCV treatment

The US state of Missouri, as part of a 25-state consortium, has entered into an agreement with AbbVie (US) to provide preferential coverage for hepatitis C virus (HCV) therapy Viekira Pak (ombitasvir + paritaprevir + ritonavir tablets; dasabuvir tablets) for Medicaid patients who meet certain medical criteria in exchange for a rebate that will be offered to all states participating in the consortium if they choose to accept it. Sovaldi will continue to be prescribed to patients who are already following the treatment, or for indications where Viekira Pak is not an effective treatment option, representing approximately 15-20% of overall HCV cases.

AbbVie Inc. Reports Unaudited Consolidated Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2014; Provides Earnings Guidance for the Year 2015; Provides First Quarter of 2015

AbbVie Inc. reported unaudited consolidated earnings results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported net sales of $5,452 million compared to $5,111 million a year ago. Operating loss was $415 million compared to earnings of $1,535 million a year ago. Loss before income taxes were $1,037 million compared to earnings of $1,439 million a year ago. Net loss was $810 million or $0.51 per diluted share compared to $1,128 million or $0.70 per diluted share a year ago. Pre-tax adjusted earnings were $1,867 million. Adjusted earnings after tax were $1,446 million or $0.89 per diluted share. For the year, the company reported net sales of $19,960 million compared to $18,790 million a year ago. Operating earnings were $3,411 million compared to $5,664 million a year ago. Earnings before income taxes were $2,369 million compared to $5,332 million a year ago. Net earnings were $1,774 million or $1.10 per diluted share compared to $4,128 million or $2.56 per diluted share a year ago. Pre-tax adjusted earnings were $6,924 million. Adjusted earnings after tax were $5,375 million or $3.32 per diluted share. The company is confirming its adjusted diluted earnings-per-share guidance for the full-year 2015 of $4.25 to $4.45, which reflects industry growth versus the prior year.  The company’s 2015 adjusted diluted earnings-per-share guidance excludes $0.34 per share of intangible asset amortization expense and other specified items.  Including these items, it’s diluted earnings-per-share guidance is $3.91 to $4.11 on a GAAP basis. The company continue to expect an adjusted tax rate in the 22% range in 2015. For the first quarter of 2015, the company expects adjusted earnings per share in the first quarter of $0.82 to $0.84. This excludes roughly $0.18 of specified items and noncash amortization, resulting in a first quarter EPS in the range of $0.64 to $0.66 on a GAAP basis.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ABBV:US $60.35 USD -2.77

ABBV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Abbott Laboratories $44.76 USD -0.50
Amgen Inc $152.26 USD -4.11
Bristol-Myers Squibb Co $60.27 USD -0.87
Eli Lilly & Co $72.00 USD -0.11
Novo Nordisk A/S kr295.50 DKK -4.40
View Industry Companies
 

Industry Analysis

ABBV

Industry Average

Valuation ABBV Industry Range
Price/Earnings 26.3x
Price/Sales 4.9x
Price/Book 20.7x
Price/Cash Flow 25.9x
TEV/Sales 3.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ABBVIE INC, please visit www.abbvie.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.